Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --
--與會者可以在以下地址申請與管理層舉行1 x 1會議 meetings@hcwco.com --
PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
加利福尼亞州帕洛阿爾託和佛羅里達州邁阿密，2023年9月7日（GLOBE NEWSWIRE）— Pasithea Therapeutics 納斯達克股票代碼：KTTA）（“Pasithea” 或 “公司”）是一家專注於發現、研究和開發中樞神經系統（CNS）疾病創新療法的生物技術公司，今天宣佈，Pasithea的管理團隊將參加將於9月11日至13日在紐約市舉行的H.C. Wainwright第25屆年度全球投資會議。
Attendees interested in 1 x 1 meetings are invited to request them through the conference's meeting scheduler at meetings@hcwco.com or by calling or emailing the company contact below.
歡迎對 1 x 1 會議感興趣的與會者通過會議的會議安排器提出申請，網址爲 meetings@hcwco.com 或者致電或發送電子郵件給下面的公司聯繫人。
About Pasithea Therapeutics Corp.
關於 Pasithea Therapeutics Co
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).
Pasithea Therapeutics是一家生物技術公司，主要專注於中樞神經系統（CNS）疾病和RasOphaties的創新療法的發現、研究和開發。Pasithea擁有一支在神經科學、轉化醫學和藥物開發領域經驗豐富的專家團隊，正在開發用於治療神經系統疾病的新分子實體，包括1型神經纖維瘤病（NF1）、肌萎縮性側索硬化症（ALS）和多發性硬化症（MS）。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新聞稿包含構成 “前瞻性陳述” 的聲明。前瞻性陳述受多種條件的約束，其中許多條件是公司無法控制的。儘管公司認爲這些前瞻性陳述是合理的，但不應過分依賴任何此類前瞻性陳述，這些陳述基於公司在本新聞稿發佈之日獲得的信息。這些前瞻性陳述基於當前的估計和假設，受到各種風險和不確定性的影響，包括但不限於公司向美國證券交易委員會（SEC）提交的文件中列出的風險和不確定性。因此，實際結果可能存在重大差異。除非法律要求，否則公司沒有義務在本新聞稿發佈之日之後更新這些聲明，無論是由於新信息、未來事件還是其他原因。
Company Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
+1 (310) 989-5666
公司聯繫人
帕特里克·蓋恩斯
企業傳播
pgaynes@pasithea.com
+1 (310) 989-5666
譯文內容由第三人軟體翻譯。